Bill

Bill > HR1672


US HR1672

US HR1672
Maintaining Investments in New Innovation Act


summary

Introduced
02/27/2025
In Committee
02/27/2025
Crossed Over
Passed
Dead

Introduced Session

119th Congress

Bill Summary

A BILL To amend title XI of the Social Security Act to protect access to genetically targeted technologies.

AI Summary

This bill amends the Social Security Act to protect access to genetically targeted technologies by modifying the definition of a "qualifying single source drug." Specifically, the bill extends the period of market exclusivity from 7 to 11 years for "advanced drug products" that use genetically targeted technologies. An advanced drug product is defined as a drug that incorporates technology capable of modifying gene function, such as suppressing, up-regulating, or activating a gene or its associated gene product. This change aims to provide longer market protection for innovative drugs that use advanced genetic technologies, potentially incentivizing pharmaceutical research and development in this emerging field of medicine. The bill seeks to support continued investment in cutting-edge genetic therapies by giving drug developers a longer period of market exclusivity before generic competitors can enter the market.

Committee Categories

Business and Industry

Sponsors (27)

Last Action

Referred to the Committee on Energy and Commerce, and in addition to the Committee on Ways and Means, for a period to be subsequently determined by the Speaker, in each case for consideration of such provisions as fall within the jurisdiction of the committee concerned. (on 02/27/2025)

bill text


bill summary

Loading...

bill summary

Loading...
Loading...